source
- Indivior ends Addex PAM collaboration as it prepares for Supernus mergerIndivior Pharmaceuticals has terminated its long‑standing partnership with Addex Therapeutics that focused on developing positive allosteric modulators (PAMs) for addiction treatment. The collabor…
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…